Fushine(SZ:300497) Bei Jing Shang Bao·2026-01-09 12:28Core Viewpoint - Fuxiang Pharmaceutical plans to transfer 39.2% equity stake in Shanghai Lingfu Pharmaceutical Research Co., Ltd. to Shanghai Lingkai Technology Co., Ltd. for 42.77 million yuan, aiming to enhance liquidity and reduce investment risks [1] Group 1: Transaction Details - The equity stake being transferred corresponds to a registered capital of 39.2 million yuan [1] - After the transaction, Fuxiang Pharmaceutical will no longer hold any equity in Shanghai Lingfu [1] Group 2: Strategic Rationale - The decision is based on the company's assessment of external investment progress and alignment with future strategic development plans [1] - The transaction aims to achieve capital recovery, reduce investment risks, and concentrate resources to strengthen core competitiveness [1] - The company expects to optimize its investment structure to enhance asset liquidity and overall risk resistance, ensuring long-term sustainable development [1]